help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, X.
Right arrow Articles by Fouty, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, X.
Right arrow Articles by Fouty, B.
(American Journal of Pathology. 2004;165:1613-1620.)
© 2004 American Society for Investigative Pathology

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Can Induce Apoptosis in Subsets of Premalignant Cells

Xiaojun Lu*{dagger}, Jack L. Arbiser{ddagger}, James West*{dagger}, Marloes Hoedt-Miller*{dagger}, Alison Sheridan*{dagger}, Baskaran Govindarajan{ddagger}, Julie Wright Harral*{dagger}, David M. Rodman*{dagger}§ and Brian Fouty

From the Division of Pulmonary Sciences and Critical Care Medicine,* the Center for Genetic Lung Diseases,{dagger} and the Division of Physiology and Biophysics,§ University of Colorado Health Sciences Center, Denver, Colorado; the Department of Dermatology,{ddagger} Emory University School of Medicine, Atlanta, Georgia; and the Center for Lung Biology and Division of Pulmonary Medicine, University of South Alabama School of Medicine, Mobile, Alabama

During the transformation from a normal to a malignant cell, several mutations are required to bypass the pathways responsible for controlling proliferation. Premalignant cells have acquired some, but not all of these mutations and consequently have not yet attained a malignant phenotype characterized by tumor formation in vivo. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in malignant cells while sparing normal ones and is currently being considered as adjuvant therapy for various human malignancies. Whether TRAIL is effective in inducing apoptosis in premalignant cells is unclear, however. We studied the effect of TRAIL on two human premalignant cell lines the SV7tert and HA1E cells. Both cell lines had been immortalized by the addition of simian virus 40 large T antigen and the telomerase subunit hTERT, but had not been transformed into malignant cells. TRAIL initiated apoptosis by activating both the mitochondrial-independent and -dependent apoptotic pathways in both cell lines at relatively low doses whereas it had no effect on normal human pulmonary artery smooth muscle cells even at high doses. These results suggest that TRAIL can induce apoptosis in premalignant cells and suggests a novel therapy for the treatment of premalignant lesions in vivo.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
A. M. Gillenwater, M. Zhong, and R. Lotan
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells
Mol. Cancer Ther., November 1, 2007; 6(11): 2967 - 2975.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Jalving, S. de Jong, J. J. Koornstra, W. Boersma-van Ek, N. Zwart, J. Wesseling, E. G.E. de Vries, and J. H. Kleibeuker
TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas.
Clin. Cancer Res., July 15, 2006; 12(14): 4350 - 4356.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society for Investigative Pathology.